AXIN1 and breast cancer: Taken together, our results assign a role for RUNX1 in antagonizing oestrogen-mediated AXIN1 suppression and highlight AXIN1 as a potential target for the treatment of RUNX1-deficient ER+ breast cancer (Fig. 7e).